Your browser doesn't support javascript.
loading
Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation.
Yedinak, Chris G; McCartney, Shirley; Dillard, Troy H; Wei, Kevin S; Fleseriu, Maria.
  • Yedinak CG; Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon, 97239, USA ; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, 97239, USA.
  • McCartney S; Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon, 97239, USA ; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, 97239, USA.
  • Dillard TH; Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon, 97239, USA.
  • Wei KS; Department of Cardiovascular Medicine, Oregon Health & Science University, Portland, Oregon, 97239, USA.
  • Fleseriu M; Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon, 97239, USA ; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, 97239, USA ; Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Hea
F1000Res ; 3: 171, 2014.
Article en En | MEDLINE | ID: mdl-25165538
ABSTRACT
We present a case of a 21 year old male patient diagnosed with a 2.2 cm prolactin-secreting adenoma in contact with the optic chiasm. The patient was treated with up to 6mg/week of cabergoline (total cumulative dose 814 mg) and developed mild valvulopathy. Valvulopathy was subsequently reversed after discontinuation of cabergoline therapy.
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Año: 2014 Tipo del documento: Article